Skip to main content
Log in

H2 Antagonist-induced thrombocytopenia: is this a real phenomenon?

  • Original
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract.

Critically ill patients routinely receive H2 antagonists for stress ulcer prophylaxis while at risk for gastrointestinal bleeding. In these patients it is often difficult to assess accurately the cause of adverse effects such as thrombocytopenia. We evaluate the literature to better define thrombocytopenia related to H2 antagonist administration and discuss mechanism, potential as a risk factor and case reports describing the severity and duration of thrombocytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wade, E.E., Rebuck, J.A., Healey, M.A. et al. H2 Antagonist-induced thrombocytopenia: is this a real phenomenon?. Intensive Care Med 28, 459–465 (2002). https://doi.org/10.1007/s00134-002-1233-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-002-1233-6

Navigation